Topas Therapeutics Appoints Hugo Fry as CEO
May 07 2024 - 5:00AM
Business Wire
- With 30 years of experience across the pharmaceutical and
biotechnology industries, Hugo Fry will lead Topas’ strategic
efforts ahead of Phase 2a data readout for lead program TPM502 in
celiac disease
Topas Therapeutics, a clinical-stage biotech company developing
novel antigen-specific immune tolerance therapies to treat
autoimmune disorders, announced today the appointment of Hugo Fry
as its new Chief Executive Officer. Bringing three decades of
experience including senior management and executive roles at both
large pharmaceutical and innovative biotechnology companies, Hugo
has a significant track record in leading companies from early
research and development through product commercialization.
“Hugo joins Topas at the right time to provide his broad
expertise and strategic direction as we advance our mission of
developing novel, disease-modifying treatment options for a range
of autoimmune and inflammatory diseases,” commented Erich F.
Greiner, Executive Chairman of Topas Therapeutics. “With data
from a Phase 2a trial of lead candidate TPM502 in celiac disease
expected later this year, we believe Hugo's leadership will drive
value for the company and fully leverage the potential of its
innovative approach.”
“Topas is at the forefront of tolerance induction therapy with a
cutting-edge nanoparticle technology platform designed to elicit
immune tolerization in T-cell-mediated diseases,” said Hugo Fry,
CEO of Topas Therapeutics. “As I take the helm, I am excited to
advance the work of this talented team and look forward to leading
Topas’ strategic efforts to progress our corporate and clinical
development.”
Hugo Fry has an extensive and diverse career spanning three
decades within the pharmaceutical and biotechnology sectors,
characterized by strategic and leadership roles, including Chief
Commercial Officer at Imbria Pharmaceuticals and Chief Business
Officer and Managing Director at 20Med Therapeutics as well as CEO
of RQ Biotechnology. With a focus on guiding companies toward
success, Hugo has previously led R&D, Industrial Affairs as
well as Commercial teams and is experienced in licensing,
fundraising and forging strategic partnerships. He has also held
several executive positions spanning multiple countries, including
Managing Director of Sanofi UK and Ireland, and Vice President and
Chief Marketing Officer for the Sanofi Pasteur MSD joint venture,
along with being the Vice-President of the Association of the
British Pharmaceutical Industry. Hugo holds a B.Sc. in Chemistry
from the University of Salford and has completed further studies in
Finance at London Business School and Leadership at Duke
University.
About Topas Therapeutics
Topas Therapeutics is committed to developing novel
disease-modifying treatment options for patients suffering from
autoimmune and inflammatory diseases. With a versatile and
personalized platform, Topas designs and produces antigen-specific
nanoparticle conjugates aimed to elicit immune tolerization in
T-cell-mediated diseases. Based in Hamburg, Germany, Topas
Therapeutics is led by a seasoned team of biotech/pharma experts
and is backed by an international consortium of investors,
including BioMedPartners, Boehringer Ingelheim Venture Fund, EMBL
Ventures, Epidarex Capital, Evotec, Gimv, Vesalius Biocapital
III.
For further information:
https://topas-therapeutics.com/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240507504752/en/
Topas Therapeutics Hugo Fry Chief Executive Officer
info@topas-therapeutics.com Trophic Communications Gretchen
Schweitzer or Dr. Alison Opalko +49 (0) 172 861 8540
topas@trophic.eu